Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RDHL | 6-K | neutral | 3/10 | RedHill Biopharma filed a 6-K reporting that all four proposals at its adjourned 2026 Annual General Meeting were approv | Aug 7, 2026 |
| CDIO | DEFA14A | neutral | 2/10 | Cardio Diagnostics Holdings filed additional definitive proxy soliciting materials (DEFA14A) on August 7, 2026. The fili | Aug 7, 2026 |
| ISPC | 424B4 | bearish | 7/10 | iSpecimen Inc. has priced a best-efforts offering of 996,231 common shares and up to 2,849,922 pre-funded warrants at $1 | Aug 7, 2026 |
| QNRX | PRESS-RELEASE | neutral | 1/10 | Quoin Pharmaceuticals, Inc. announced it will report its Q2 2026 results on August 14, 2026. | Aug 7, 2026 |
| ATOS | PRESS-RELEASE | neutral | 4/10 | Atossa Therapeutics reported Q2 2026 net loss of $8.5M ($0.95 per share), beating consensus of $1.04 loss per share by 8 | Aug 7, 2026 |
| BIAF | 8-K | mixed | 5/10 | bioAffinity Technologies reported Q2 2026 revenue of $1.5M (+19% YoY) and a net loss of $3.4M (improved from $4.1M), dri | Aug 7, 2026 |
| XBIO | 8-K | neutral | 4/10 | Xenetic Biosciences reported Q2 2026 financial results, with royalty revenue increasing 12% YoY to ~$0.7M, but the net l | Aug 7, 2026 |
| ATOS | 8-K | neutral | 4/10 | Atossa Therapeutics reported Q2 2026 net loss of $8.5M ($0.95 per share), beating consensus of $1.04 loss per share by ~ | Aug 7, 2026 |
| HUMA | PRESS-RELEASE | neutral | 1/10 | Humacyte, Inc announced it will report its Q2 2026 results on August 12, 2026. | Aug 7, 2026 |
| ETST | 8-K | neutral | 4/10 | Earth Science Tech reported Q1 FY2027 revenue of $9.0M (+3% YoY) and net income of $715,697 (+57% YoY), with diluted EPS | Aug 7, 2026 |
| GYRE | 8-K | bearish | 6/10 | Gyre Therapeutics reported Q2 2026 revenue of $29.1 million (down 2% YoY) and a GAAP basic EPS of $(0.12) vs consensus e | Aug 7, 2026 |
| IMA | EFFECT | bearish | 5/10 | ImageneBio's registration statement (File No. 333-290108) became effective on August 6, 2026, under the Securities Act o | Aug 7, 2026 |
| BLSM | EFFECT | bullish | 7/10 | BlossomHill Therapeutics' S-1 registration statement for its initial public offering was declared effective by the SEC o | Aug 7, 2026 |
| LTGO | EFFECT | bullish | 7/10 | The SEC declared effective Latigo Biotherapeutics' S-1 registration statement for its initial public offering of common | Aug 7, 2026 |
| VRXA | EFFECT | bearish | 6/10 | The SEC declared effective Veraxa Biotech's F-1 registration statements (File No. 333-297908) covering the resale of up | Aug 7, 2026 |
| REPL | 8-K | bullish | 8/10 | Replimune announced on August 6, 2026 that the FDA granted accelerated approval for TUDRIQEV (vusolimogene oderparepvec- | Aug 7, 2026 |
| PFE | CLUSTER | bullish | 4/10 | Two Pfizer directors (Blaylock and Buckley) made open-market purchases totaling ~$1.96M on the same day the company's SV | Aug 7, 2026 |
| UTHR | CLUSTER | mixed | 6/10 | United Therapeutics CEO Martine Rothblatt and EVP Paul Mahon collectively sold ~$490K in open-market shares within two d | Aug 7, 2026 |
| CSTL | CLUSTER | neutral | 2/10 | Three C-suite insiders at Castle Biosciences, including the CEO and COO, sold shares worth a combined ~$240K over a two- | Aug 7, 2026 |
| LTGO | 3 | neutral | 2/10 | This is a routine initial statement of beneficial ownership (Form 3) filed by 5AM Ventures VI, L.P., 5AM Partners VI, LL | Aug 6, 2026 |
| LTGO | 3 | neutral | 3/10 | Westlake BioPartners entities filed a Form 3 initial statement of beneficial ownership, disclosing an aggregate pre-IPO | Aug 6, 2026 |
| BLSM | 3 | neutral | 2/10 | John P. Schmid filed an initial Statement of Beneficial Ownership (Form 3) upon becoming a director of BlossomHill Thera | Aug 6, 2026 |
| BLSM | 3 | neutral | 1/10 | Sheila Gujrathi filed a Form 3 initial statement of beneficial ownership disclosing 90,160 shares of BlossomHill Therape | Aug 6, 2026 |
| BLSM | 3 | neutral | 3/10 | OrbiMed Advisors partner Carl L. Gordon filed an initial Statement of Beneficial Ownership (Form 3) with the SEC for Blo | Aug 6, 2026 |
| BLSM | 3 | neutral | 2/10 | CFO Jason Keyes filed a Form 3 initial statement of beneficial ownership, disclosing 175,417 employee stock options exer | Aug 6, 2026 |
| LTGO | 3 | neutral | 2/10 | Two insiders at Latigo Biotherapeutics, CFO/Chief Business Officer Neha Krishnamohan and director Timothy P. Walbert, fi | Aug 6, 2026 |
| LTGO | 3 | neutral | 2/10 | Three Form 3 initial beneficial ownership filings for Latigo Biotherapeutics (LTGO) were filed on August 6, 2026, by CEO | Aug 6, 2026 |
| BLSM | 3 | neutral | 1/10 | Executive Chairman Yishan Peter Li filed a Form 3 initial statement of beneficial ownership for BlossomHill Therapeutics | Aug 6, 2026 |
| BLSM | 3 | neutral | 2/10 | This is a routine initial beneficial ownership filing (Form 3) by Jingrong Jean Cui, President and CEO of BlossomHill Th | Aug 6, 2026 |
| LTGO | 3 | neutral | 3/10 | Two large, Foresite Capital and Westlake BioPartners-affiliated beneficial owners filed initial Section 16 statements of | Aug 6, 2026 |